Trial Profile
Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tivozanib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 12 Feb 2020 Results published in AVEO Oncology Media Release
- 10 Feb 2020 Primary endpoint has not been met. (PFS, assessed using standard RECIST criteria)
- 10 Feb 2020 Results published in the British Journal of Cancer